Executive Summary
These three new federal contracts totaling $259,112,045 in obligations are entirely civilian (0/3 defense-related), spanning NASA, HHS/BARDA, and Department of State with an average signal strength of 5.7/10.
The dominant theme is long-duration R&D and IT services in health preparedness and national security support, led by Basilea Pharmaceutica International Ltd's $92.5M BARDA award for antimicrobials R&D—the highest-conviction bullish signal due to its $267.6M ceiling and 7-11 year horizon. Neutral signals dominate from historical LJT & Associates ($94.6M NASA, ended 2019 with low $8.8M outlay) and ongoing Idemia National Security Solutions ($72M State Dept, $18.2M outlayed through 2026). Key risk: stalled outlays on LJT and Idemia signal execution hurdles; watch Basilea option exercises toward $267.6M.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior New Federal Contractors digest from April 28, 2026.
Investment Signals (3)
- Basilea Pharmaceutica International Ltd Secures $92.5M BARDA R&D Contract with $267.6M Ceiling (HIGH)▲
HHS/BARDA awarded Basilea a cost-sharing contract on 2024-09-18 for antimicrobials R&D against resistant infections, with $92.5M obligated ($36.2M outlayed) and potential to $267.6M through 2035 under full competition. This provides ~$13.2M-$24.3M annual revenue visibility in health preparedness.
- LJT & Associates NASA Contract Shows Low $8.8M Outlay vs $94.6M Obligation (MEDIUM)▲
The 2016-2019 NASA Goddard contract for launch operations support has only $8.8M outlayed against $94.6M obligation and $108.1M ceiling, signaling limited revenue realization post-performance end.
- Idemia National Security Solutions $72M State Dept Delivery Order with Partial Funding (MEDIUM)▲
Department of State awarded Idemia a firm fixed price order in 2018 for facial recognition integration, with $72M obligated ($18.2M outlayed) through 2026-09-29 and ceiling to $74.1M.
Risk Flags (3)
- Execution [HIGH RISK]▼
LJT & Associates NASA contract ended 2019-08-09 with only $8.8M outlayed vs $94.6M obligation, indicating potential revenue shortfalls and no evident follow-ons.
- Execution [MEDIUM RISK]▼
Idemia National Security Solutions State Dept contract has high pricing risk (firm fixed price) with $18.2M outlayed vs $72M obligation through 2026.
- Budget [MEDIUM RISK]▼
Basilea Pharmaceutica BARDA contract carries R&D execution risks despite low pricing risk, with only $36.2M outlayed on $92.5M obligation.
Opportunities (2)
- ◆
Basilea Pharmaceutica International Ltd's BARDA contract offers expansion from $92.5M obligation to $267.6M ceiling via options for antimicrobials R&D.
- ◆
Idemia National Security Solutions could realize remaining $53.9M unobligated funds and $2.1M options on State Dept facial recognition order.
Sector Themes (3)
- ◆
Basilea's $92.5M cost-sharing award (ceiling $267.6M) for antimicrobials against resistant infections underscores BARDA's focus on long-term biotech R&D through 2031-2035.
- ◆
LJT & Associates' historical $94.6M cost-plus contract for Wallops Island launch support (PSC AJ45) highlights NASA Goddard's reliance on non-competed services, though low outlays limit signals.
- ◆
Idemia's $72M firm fixed price delivery order for facial recognition in visa/passport processes provides multi-year IT support visibility through 2026.
Watch List (3)
- 👁
{"entity"=>"Basilea Pharmaceutica International Ltd", "reason"=>"$92.5M BARDA obligation with $267.6M ceiling and $36.2M outlayed; key to revenue ramp.", "trigger"=>"option exercises toward 2035-12-31"}
- 👁
{"entity"=>"LJT & Associates, Inc.", "reason"=>"$94.6M NASA obligation with only $8.8M outlayed post-2019 end.", "trigger"=>"follow-on contracts post-2019"}
- 👁
{"entity"=>"Idemia National Security Solutions LLC", "reason"=>"$72M State Dept obligation with $18.2M outlayed through 2026.", "trigger"=>"outlay progress and option exercises to $74.1M by 2026-09-29"}
Get daily alerts with 3 investment signals, 3 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: New Federal Contractors
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals